Background: Cost-effectiveness of olanzapine in comparison with haloperidol, in Spanish schizophrenic patients, was analysed using a clinical decision model.
Methods: The model represents a simulation of the different clinical and therapeutic possibilities that an hypothetical cohort of patients could experienced in a 5-years period of treatment. Efficacy was measured as months with partial-complete remission. Most information was obtained from the HGAJ randomised clinical trial. Other information was estimated through literature reviews and the opinion of an expert panel.
Results: Average cost-effectiveness for olanzapine was lower (116,476 pesetas per month with partial-complete remission) than for haloperidol (134,762 pesetas per month with partial-complete remission). Olanzapine produced more than half year (6.7 months) with partial complete remission, in comparison with haloperidol, with antincrementar cost-effectiveness of 32,516 pesetas per month with partial-complete remission, in comparison with haloperidol. The results were not sensitive to changes in the values of the main variables used in the analysis.
Conclusions: According to this analysis, olanzapine presents a good cost-effectiveness relationship in comparison with baloperidol, in Spanish schizophrenic patients. The analysis will be completed when new studies comparing olanzapine with other antipsychotics are available.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: A systematic review and meta-analysis.
Eur J Neurol
July 2024
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Article Synopsis
- The study aims to review the neuroimaging features and clinical symptoms of autoimmune GFAP astrocytopathy (GFAP-A) to help with early diagnosis and treatment of this rare neuroinflammatory disorder.
- A systematic review and meta-analysis was conducted, analyzing data from 93 studies with 681 cases, revealing common symptoms like headache, fever, and movement disturbances, often preceded by a viral illness.
- The findings suggest that neuroimaging frequently shows hyperintensities and enhancements, and corticosteroid treatment was effective in a significant number of cases, laying groundwork for future identification and diagnostics of GFAP-A.
Pediatric Optic Pathway Gliomas: A Report From Northern Greece.
J Pediatr Hematol Oncol
November 2023
Departments of Pediatric Oncology.
Optic pathway gliomas (OPGs) are the most common pediatric optic nerve tumors. Their behavior ranges between rapid growth, stability, or spontaneous regression. Τhey are characterized by low mortality albeit with significant morbidity.
View Article and Find Full Text PDFSevere cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.
J Immunother Cancer
April 2023
EBMT Transplant Complications Working Party, Paris, France.
We investigated the incidence and outcome of anti-CD19 chimeric antigen receptor (CAR) T-cells-associated Common Terminology Criteria for Adverse Events (CTCAE) ≥grade 3 cytopenia. In the EBMT CAR-T registry, we identified 398 adult patients with large B-cell lymphoma who had been treated with CAR-T-cells with axicel (62%) or tisacel (38%) before August 2021 and had cytopenia status documented for the first 100 days. Most patients had received two or three previous lines of therapy, however, 22.
View Article and Find Full Text PDFPersonalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis.
NPJ Genom Med
January 2023
Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Despite progress, 2-year pancreatic cancer survival remains dismal. We evaluated a biomarker-driven, combination/N-of-one strategy in 18 patients (advanced/metastatic pancreatic cancer) (from Molecular Tumor Board). Targeted agents administered/patient = 2.
View Article and Find Full Text PDFPrognostic Role of Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
J Nucl Med
June 2023
Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany; and.
This study was performed to assess the prognostic utility of conventional biochemical and imaging response criteria and Ga-PSMA11 PET-adapted or -specific systems regarding overall survival (OS) in men with metastatic hormone-sensitive and castration-resistant prostate cancer (PC) treated with taxane-based chemotherapy. A total of 103 patients (metastatic hormone-sensitive PC, = 57; castration-resistant PC, = 46) underwent taxane-based chemotherapy. All patients had a minimum of 2 prostate-specific membrane antigen (PSMA) PET scans (at baseline and up to 3 mo after treatment).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!